Everest Medicines Limited
1952.HK
Get informed when a big investor buys or sells
+ FollowMarket Cap$10.4B
Close$
Share Statistics
| Market cap | $10.40 Billion |
|---|---|
| Enterprise Value | $10.87 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.89 |
| Beta | 1.56 |
| Outstanding Shares | 297,200,000 |
Return
| Return on Equity | -1.03% |
|---|---|
| Return on Assets | -0.64% |
| Return on Invested Capital | -1.30% |
Valuation & Multiples
| P/E Ratio | -159.48 |
|---|---|
| PEG | 163.37 |
| Price to Sales | 3.7 |
| Price to Book Ratio | 1.74 |
| Enterprise Value to Revenue | 4.51 |
| Enterprise Value to EBIT | -109 |
| Enterprise Value to Net Income | -202 |
| Total Debt to Enterprise | 0.18 |
| Debt to Equity | 0.38 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 17, 2026
EPS Estimate
$-1.07
Average shareholder expectationRevenue Estimate
$1.59 B
Average shareholder expectationNext Earnings Call
Expected Date
April 1, 2027
EPS Estimate
$2.18
Average shareholder expectationRevenue Estimate
$2.48 B
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Everest Medicines Limited
812 employees
CEO: Yongqing Luo Everest Medicines Limited operates as a biopharmaceutical firm, concentrating its efforts on bringing innovative treatments to market. The company handles the entire process, from identifying and acquiring promising drug candidates to de...